NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is a common risk associated with aromatase inhibitors and SERMS?

Hypoglycemia
Thromboembolic risk (clotting)
Hypertension
Gastrointestinal issues

The correct answer is: Thromboembolic risk (clotting)

Aromatase inhibitors and selective estrogen receptor modulators (SERMs) are commonly used in the treatment of hormone-sensitive breast cancer. One of the common risks associated with these medications is an increased risk of thromboembolic events, which refers to the formation of blood clots within blood vessels that can lead to serious complications such as pulmonary embolism or stroke. This risk is important to monitor and manage in patients receiving these medications to prevent potentially life-threatening complications. Options A, C, and D are not commonly associated with aromatase inhibitors and SERMs.